Keros Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference

Rhea-AI Summary

Keros Therapeutics, Inc. (Nasdaq: KROS), a clinical-stage biopharmaceutical company, announced that its CEO, Jasbir S. Seehra, Ph.D., will present at the 10th Annual SVB Leerink Global Healthcare Conference on February 24, 2021, at 1:40 PM ET. The presentation will be available via live webcast and archived for 90 days on Keros's website. Keros is focused on developing innovative treatments for hematological and musculoskeletal disorders, including KER-050 for cytopenias, KER-047 for iron imbalance, and KER-012 for bone loss and pulmonary arterial hypertension.

LEXINGTON, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced that Keros’s President and Chief Executive Officer Jasbir S. Seehra, Ph.D. will present at the 10^th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 24^th at 1:40 pm ET.

The fireside chat presentation will be webcast live at https://wsw.com/webcast/svbleerink47/kros/2684928 and archived in the Investors section of the Keros website at https://ir.kerostx.com/. A replay will be available for 90 days following the conclusion of the event.

About Keros Therapeutics, Inc.

Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematologic and musculoskeletal disorders with high unmet medical need. Keros is a leader in understanding the role of the transforming growth factor-Beta, or TGF-ß, family of proteins, which are master regulators of red blood cell and platelet production as well as of the growth, repair and maintenance of muscle and bone. Keros’ lead protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and in patients with myelofibrosis. Keros’ lead small molecule product candidate, KER-047, is being developed for the treatment of anemia resulting from iron imbalance, as well as for the treatment of fibrodysplasia ossificans progressiva. Keros’ third product candidate, KER-012, is being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension.

Investor Contact:
Julia Balanova
jbalanova@soleburytrout.com
646-378-2936

FAQ

What is the date of Keros Therapeutics' presentation at the SVB Leerink Global Healthcare Conference?

Keros Therapeutics' presentation is scheduled for February 24, 2021.

What time will Keros Therapeutics' CEO present at the conference?

The presentation will take place at 1:40 PM ET.

Where can I watch the Keros Therapeutics presentation?

The presentation can be watched live via webcast and archived on Keros's website.

What are the main product candidates of Keros Therapeutics?

Keros Therapeutics' main product candidates include KER-050, KER-047, and KER-012.

What disorders does KER-050 target?

KER-050 is being developed for the treatment of low blood cell counts such as anemia and thrombocytopenia.

What conditions is KER-047 designed to treat?

KER-047 is being developed for anemia resulting from iron imbalance and fibrodysplasia ossificans progressiva.

What disorders is KER-012 intended to address?

KER-012 targets bone loss disorders like osteoporosis and pulmonary arterial hypertension.